U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06857175) titled 'A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma' on Feb. 26.
Brief Summary: This trial is a registered phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic urothelial carcinoma after failure of PD-1/PD-L1 monoclonal antibody and platinum-based chemotherapy.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Urothelial Carcinoma
Intervention:
DRUG: BL-B01D1
Administration by intravenous infusion for a cycle of 3 weeks.
DRUG: Docetaxel or P...